Rising research and development costs sent half-year adjusted pre-tax profit down a tenth at animal genetics group Genus (GNS). Top-line growth wasn't as good as first thought, either. Although group revenue rose 3 per cent at constant currencies, performance at the ABS bovine business fell short of management's expectations.
To continue reading, register today
to enjoy limited access to the following:
- Daily trading news
- Funds coverage
- Features on big investment themes
- Comprehensive companies coverage
- Economic analysis